Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery s…
Medical - Specialties
US, New York [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Delcath Systems, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | -526.1400 | -7.547 | 1 | 1 | -13 | -122 | -2 | -1 | -19 | -1 | 11 | 10 |
| 2021 | -8.4500 | -3.882 | 1 | 1 | -24 | -63 | -23 | -1 | -21 | -1 | 11 | 13 |
| 2022 | -3.7400 | -3.772 | 3 | 2 | -26 | -61 | -23 | -2 | -24 | -2 | 13 | 20 |
| 2023 | -4.4200 | -3.014 | 2 | 2 | -39 | -47 | -33 | -2 | -33 | -2 | 17 | 14 |
| 2024 | -2.9400 | -0.812 | 2 | 34 | -47 | -13 | -46 | -34 | -38 | -34 | 22 | 240 |
| 2025 | - | -0.109 | - | 72 | - | -1 | - | -72 | - | -72 | - | 505 |
| 2026 | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F61/td> | - | 2.F61 | - | 2.F61 |
| 2027 | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F71/td> | - | 1.F71 | - | 1.F71 |
| 2028 | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F81/td> | - | 0.F81 | - | 0.F81 |